ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,373 | -38.5% | 17,728 | -12.7% | 0.00% | – |
| Q2 2023 | $28,227 | -73.3% | 20,307 | -69.5% | 0.00% | – |
| Q1 2023 | $105,893 | -72.6% | 66,599 | +7.5% | 0.00% | – |
| Q4 2022 | $385,837 | +257.3% | 61,932 | +284.1% | 0.00% | – |
| Q3 2022 | $108,000 | -64.5% | 16,123 | -66.3% | 0.00% | – |
| Q2 2022 | $304,000 | +253.5% | 47,789 | +155.6% | 0.00% | – |
| Q1 2022 | $86,000 | -91.5% | 18,695 | -90.8% | 0.00% | -100.0% |
| Q4 2021 | $1,014,000 | -67.5% | 202,767 | -21.7% | 0.00% | -50.0% |
| Q3 2021 | $3,122,000 | +47.9% | 259,068 | +159.7% | 0.00% | +100.0% |
| Q2 2021 | $2,111,000 | -35.2% | 99,760 | -14.1% | 0.00% | -50.0% |
| Q1 2021 | $3,259,000 | +52.1% | 116,133 | +40.9% | 0.00% | +100.0% |
| Q4 2020 | $2,143,000 | -94.2% | 82,451 | -91.7% | 0.00% | -95.7% |
| Q3 2020 | $37,000,000 | -15.7% | 995,414 | +16.3% | 0.02% | -25.8% |
| Q2 2020 | $43,913,000 | +56.2% | 855,838 | -4.0% | 0.03% | +29.2% |
| Q1 2020 | $28,116,000 | -46.9% | 891,706 | +0.4% | 0.02% | -36.8% |
| Q4 2019 | $52,936,000 | +51.6% | 887,741 | -6.8% | 0.04% | +31.0% |
| Q3 2019 | $34,924,000 | -29.3% | 952,656 | -10.2% | 0.03% | -34.1% |
| Q2 2019 | $49,374,000 | +7.0% | 1,061,340 | -7.7% | 0.04% | +4.8% |
| Q1 2019 | $46,149,000 | +3.3% | 1,149,415 | +18.3% | 0.04% | -8.7% |
| Q4 2018 | $44,695,000 | +3.8% | 971,635 | +0.1% | 0.05% | +17.9% |
| Q3 2018 | $43,063,000 | +0.5% | 970,546 | -11.3% | 0.04% | -7.1% |
| Q2 2018 | $42,858,000 | -45.4% | 1,093,599 | +0.8% | 0.04% | -42.5% |
| Q1 2018 | $78,464,000 | +17.3% | 1,084,820 | +6.8% | 0.07% | +21.7% |
| Q4 2017 | $66,899,000 | +25.4% | 1,016,106 | -4.5% | 0.06% | +15.4% |
| Q3 2017 | $53,330,000 | +3.5% | 1,064,038 | -4.5% | 0.05% | +4.0% |
| Q2 2017 | $51,546,000 | +66.1% | 1,113,795 | +26.7% | 0.05% | +78.6% |
| Q1 2017 | $31,030,000 | +256.4% | 878,824 | +26.4% | 0.03% | +211.1% |
| Q4 2016 | $8,706,000 | +61.3% | 695,384 | +78.4% | 0.01% | +80.0% |
| Q3 2016 | $5,398,000 | +83.9% | 389,753 | +31.2% | 0.01% | +66.7% |
| Q2 2016 | $2,935,000 | +164.7% | 297,024 | +353.3% | 0.00% | +200.0% |
| Q1 2016 | $1,109,000 | -38.1% | 65,522 | -18.7% | 0.00% | -50.0% |
| Q4 2015 | $1,793,000 | +53.4% | 80,574 | +62.6% | 0.00% | +100.0% |
| Q3 2015 | $1,169,000 | -79.5% | 49,551 | -29.1% | 0.00% | -83.3% |
| Q2 2015 | $5,714,000 | +41.5% | 69,886 | +60.2% | 0.01% | +50.0% |
| Q1 2015 | $4,039,000 | +408.7% | 43,613 | +122.2% | 0.00% | +300.0% |
| Q4 2014 | $794,000 | – | 19,630 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |